ZYMOGENETICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1981-01-01
- Employees
- 323
- Market Cap
- -
- Website
- http://www.zymogenetics.com
Clinical Trials
17
Active:7
Completed:9
Trial Phases
4 Phases
Phase 1:5
Phase 2:2
Phase 3:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (45.5%)Phase 2
2 (18.2%)Phase 3
2 (18.2%)Phase 4
2 (18.2%)Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
Phase 2
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 600
- Registration Number
- NCT01001754
Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants
Phase 4
Completed
- Conditions
- Blood Loss, Surgical
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 30
- Registration Number
- NCT00859547
- Locations
- 🇺🇸
Arizona Burn Center, Phoenix, Arizona, United States
Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis
Phase 4
Completed
- Conditions
- Blood Loss, Surgical
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 31
- Registration Number
- NCT00813904
- Locations
- 🇺🇸
Tuscon Orthopaedic Institute, Tuscon, Arizona, United States
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic
- First Posted Date
- 2007-11-30
- Last Posted Date
- 2009-10-07
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 56
- Registration Number
- NCT00565539
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Immunogenicity and Safety Study of Topical Recombinant Thrombin in Surgical Hemostasis
Phase 3
Completed
- Conditions
- Spinal SurgeryVascular Surgery
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- ZymoGenetics
- Target Recruit Count
- 234
- Registration Number
- NCT00491608
- Locations
- 🇺🇸
Huntington Memorial Hospital, Pasadena, California, United States
- Prev
- 1
- 2
- Next
News
No news found